Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model for predicting sorafenib response and overall survival (OS). | Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma A prospective cohort study